Oncomodulin
Navigation Links
Oncomodulin in Medical News
Alseres Shares Begin Trading on the Pink Sheets OTC Market
...n a Phase I/IIa clinical trial. The Company's research and pre-clinical programs include, Inosine for the treatment of spinal cord injury and stroke, oncomodulin for the treatment of ocular injury and disease and research programs directed at a number of regenerative therapies including bone repair. F...Alseres and BioAxone Amend License Agreement for Cethrin(R) and Rho Inhibitor Technology
...n a Phase I/IIa clinical trial. The Company's research and pre-clinical programs include, Inosine for the treatment of spinal cord injury and stroke, oncomodulin for the treatment of ocular injury and disease and research programs directed at a number of regenerative therapies including bone repair. F......n a Phase I/IIa clinical trial. The Company's research and pre-clinical programs include, Inosine for the treatment of spinal cord injury and stroke, oncomodulin for the treatment of ocular injury and disease and research programs directed at a number of regenerative therapies including bone repair. F...
Alseres Pharmaceuticals, Inc. Announces $200,000 Financing
...n a Phase I/IIa clinical trial. The Company's research and pre-clinical programs include, Inosine for the treatment of spinal cord injury and stroke, oncomodulin for the treatment of ocular injury and disease and research programs directed at a number of regenerative therapies including bone repair. The Compan...Alseres Pharmaceuticals, Inc. Receives Notice of Non-Compliance with Continued Listing Requirements
...n a Phase I/IIa clinical trial. The Company's research and pre-clinical programs include, Inosine for the treatment of spinal cord injury and stroke, oncomodulin for the treatment of ocular injury and disease and research programs directed at a number of regenerative therapies including bone repair. The Compan...Alseres Pharmaceuticals, Inc. Announces $1 Million Financing
...n a Phase I/IIa clinical trial. The Company's research and pre-clinical programs include, Inosine for the treatment of spinal cord injury and stroke, oncomodulin for the treatment of ocular injury and disease and research programs directed at a number of regenerative therapies including bone repair. The Compan...Alseres Pharmaceuticals, Inc. To Host Third Quarter 2008 Conference Call
...in a Phase I/IIa clinical trial. The Company's research and pre-clinical programs include, Inosine for the treatment of spinal cord injury and stroke, oncomodulin for the treatment of ocular injury and disease and research programs directed at a number of regenerative therapies including bone repair. The Company...Alseres Pharmaceuticals, Inc. to Present at Rodman & Renshaw 10th Annual Healthcare Conference
...in a Phase I/IIa clinical trial. The Company's research and pre-clinical programs include, Inosine for the treatment of spinal cord injury and stroke, oncomodulin for the treatment of ocular injury and disease and research programs directed at a number of regenerative therapies including bone repair. The Company...Alseres Pharmaceuticals, Inc. Reports Second Quarter 2008 Operational and Financial Results
...in a Phase I/IIa clinical trial. The Company's research and pre-clinical programs include, Inosine for the treatment of spinal cord injury and stroke, oncomodulin for the treatment of ocular injury and disease and research programs directed at a number of regenerative therapies including bone repair. The Company......in a Phase I/IIa clinical trial. The Company's research and pre-clinical programs include, Inosine for the treatment of spinal cord injury and stroke, oncomodulin for the treatment of ocular injury and disease and research programs directed at a number of regenerative therapies including bone repair. The Company...
Oncomodulin in Medical Technology
...n a Phase I/IIa clinical trial. The Company's research and pre-clinical programs include, Inosine for the treatment of spinal cord injury and stroke, oncomodulin for the treatment of ocular injury and disease and research programs directed at a number of regenerative therapies including bone repair. The Compan...
...in a Phase I/IIa clinical trial. The Company's research and pre-clinical programs include, Inosine for the treatment of spinal cord injury and stroke, oncomodulin for the treatment of ocular injury and disease and research programs directed at a number of regenerative therapies including bone repair. The Company...
...in a Phase I/IIa clinical trial. The Company's research and pre-clinical programs include, Inosine for the treatment of spinal cord injury and stroke, oncomodulin for the treatment of ocular injury and disease and research programs directed at a number of regenerative therapies including bone repair. The Company...
...in a Phase I/IIa clinical trial. The Company's research and pre-clinical programs include, Inosine for the treatment of spinal cord injury and stroke, oncomodulin for the treatment of ocular injury and disease and research programs directed at a number of regenerative therapies including bone repair. The Company...
...n a Phase I/IIa clinical trial. The Company's research and pre- clinical programs include, Inosine for the treatment of spinal cord injury and stroke, oncomodulin for the treatment of ocular injury and disease and research programs directed at a number of regenerative therapies including bone repair. The company...
...in a Phase I/IIa clinical trial. The Company's research and pre-clinical programs include, Inosine for the treatment of spinal cord injury and stroke, oncomodulin for the treatment of ocular injury and disease and research programs directed at a number of regenerative therapies including bone repair. The Company...
...in a Phase I/IIa clinical trial. The Company's research and pre-clinical programs include, Inosine for the treatment of spinal cord injury and stroke, oncomodulin for the treatment of ocular injury and disease and research programs directed at a number of regenerative therapies including bone repair. The Company...
...in a Phase I/IIa clinical trial. The Company's research and pre-clinical programs include, Inosine for the treatment of spinal cord injury and stroke, oncomodulin for the treatment of ocular injury and disease and research programs directed at a number of regenerative therapies including bone repair. The Company...
Alseres Pharmaceuticals Initiates the ALTROPANE(R) POET-2 Phase III Clinical Trial Program
...in a Phase I/IIa clinical trial. The Company's research and pre-clinical programs include, Inosine for the treatment of spinal cord injury and stroke, oncomodulin for the treatment of ocular injury and disease and research programs directed at a number of regenerative therapies including bone repair. The Company......n a Phase I/IIa clinical trial. The Company's research and pre- clinical programs include, Inosine for the treatment of spinal cord injury and stroke, oncomodulin for the treatment of ocular injury and disease and research programs directed at a number of regenerative therapies including bone repair. The company...
Oncomodulin in Biological Technology
Alseres Pharmaceuticals, Inc. Complies with NASDAQ Rule Regarding Recently Filed 10-K
...n a Phase I/IIa clinical trial. The Company's research and pre-clinical programs include, Inosine for the treatment of spinal cord injury and stroke, oncomodulin for the treatment of ocular injury and disease and research programs directed at a number of regenerative therapies including bone repair. The Compan...Alseres Pharmaceuticals, Inc. Announces $1 Million Financing
...n a Phase I/IIa clinical trial. The Company's research and pre-clinical programs include, Inosine for the treatment of spinal cord injury and stroke, oncomodulin for the treatment of ocular injury and disease and research programs directed at a number of regenerative therapies including bone repair. The Compan...Alseres Pharmaceuticals, Inc. Reports Third Quarter 2008 Operational and Financial Results
...in a Phase I/IIa clinical trial. The Company's research and pre-clinical programs include, Inosine for the treatment of spinal cord injury and stroke, oncomodulin for the treatment of ocular injury and disease and research programs directed at a number of regenerative therapies including bone repair. The Company...Alseres Pharmaceuticals, Inc. Raises $5 Million
...in a Phase I/IIa clinical trial. The Company's research and pre-clinical programs include, Inosine for the treatment of spinal cord injury and stroke, oncomodulin for the treatment of ocular injury and disease and research programs directed at a number of regenerative therapies including bone repair. The Company...Alseres Pharmaceuticals, Inc. Reports 2007 Financial Results and Provides Company Highlights
...ies in which other of our regenerative technologies, including Inosine, oncomodulin and other compounds, are being tested in parallel in a series of models...ograms include, Inosine for the treatment of spinal cord injury and stroke, oncomodulin for the treatment of ocular injury and disease and research programs direct......in a Phase I/IIa clinical trial. The Company's research and pre-clinical programs include, Inosine for the treatment of spinal cord injury and stroke, oncomodulin for the treatment of ocular injury and disease and research programs directed at a number of regenerative therapies including bone repair. The Company...
Alseres Pharmaceuticals, Inc. to Present at Windhover's Therapeutic Area Partnerships Conference
...in a Phase I/IIa clinical trial. The Company's research and pre-clinical programs include, Inosine for the treatment of spinal cord injury and stroke, oncomodulin for the treatment of ocular injury and disease and research programs directed at a number of regenerative therapies including bone repair. The Company...Alseres Pharmaceuticals, Inc. to Present at Bio Investor Forum 2007 Annual Meeting
...in a Phase I/IIa clinical trial. The Company's research and pre-clinical programs include, Inosine for the treatment of spinal cord injury and stroke, oncomodulin for the treatment of ocular injury and disease and research programs directed at a number of regenerative therapies including bone repair. The Company...Other TagsPolyplusFluoRFluoRFluoRFluoRENDOENDOENDOENDOENDOENDOENDOENDOENDODakoMazeObjectObjectOther Contentsmedicinemedicinemedicinemedicinemedicinemedicinemedicinemedicinemedicineprizeprizeprizeprizewolfwolfmedicalmedicalmedicalmedicalmedicalmedicalmedicalmedicalmedicalmedicalworldworldworldworldworldworldworldworldworldabdomenabdomenabdomenabdomenaboralabiotic
(Date:12/1/2009)...swire/ -- A national survey reveals the majority o...bies and themselves but at the same time want the ... families. ,, See video from HealthyWomen at: ...ey of mothers of children aged 12 months and young... feeding decision prior to going to the hospital t...
(Date:12/1/2009)...swire/ -- Edifecs, Inc., the proven leader in HIPA...ons announced an enhanced release of Edifecs XEngi...AA 5010 migrations. XEngine Translator provides ou...eneration of test data and permits two-way transla...ddressing most requirements for organizations plan...
(Date:12/1/2009)... screening test, expert says , , TUESDAY...ld lead to a simple blood test to screen for lung ...stem markers that indicate early-stage lung tumors...researchers examined gene expression profiles in b...lung cancer and a control group of 91 people with ...
(Date:12/1/2009)...liver surgery after chemo, study finds, , ... of liver tumors caused by the spread of colorecta...hemotherapy, researchers report. , Adding bevac...n shown to improve survival in patients with late-...lts in patients having surgery to remove colorecta...
(Date:12/1/2009)...s course remains unpredictable , , TUESD...ial said Tuesday that H1N1 swine flu infections ap...s agreed the virus could return in force later thi...tes -- down from 43 states the week before, Dr. Th...Disease Control and Prevention (CDC), said during ...
Breaking Medicine News(10 mins):Health News:VIDEO from Medialink and HealthyWomen: Breast, Bottle or Both? 2Health News:Edifecs Delivers Enhanced HIPAA 4010A1 to 5010 Migration Capabilities for Healthcare Organizations 2Health News:Edifecs Delivers Enhanced HIPAA 4010A1 to 5010 Migration Capabilities for Healthcare Organizations 3Health News:Gene 'Signature' May Point to Lung Cancer 2Health News:CT Scan May Predict Colon Cancer Survival 2Health News:Swine Flu Waning, But Could Return 2Health News:Swine Flu Waning, But Could Return 3(Date:12/1/2009)...Ohio Ohio State University cancer researchers hav...ls brain-tumor cells and blocks the growth of new ... viruses designed to kill cancer cells oncolytic ...e brain tumors if they also carry a gene for a pro...tein, called vasculostatin, is normally produced i...
(Date:12/1/2009)...e scientists, one from the United States, the othe... the leader of his wolf pack, on remote Ellesmere ...goal to finally find out what these "North Pole w...of the harshest areas of the world., "We first e...avid Mech, a renowned U.S. Geological Survey (USGS...
(Date:12/1/2009)... first, a Monash University-led international rese... the output of the next generation of solar cells....tion with colleagues from the universities of Woll...e-sensitised solar cells with a three-fold increas...eviously reported tandem dye-sensitised solar cell...
Breaking Biology News(10 mins):Tumor-attacking virus strikes with 'one-two punch' 2North Pole wolf emails locations to researchers 2North Pole wolf emails locations to researchers 3Innovation puts next-generation solar cells on the horizon 2Dr Dan Lebovitz of Ohio Receives Leadership Award 50611 1Dr Dan Lebovitz of Ohio Receives Leadership Award 50611 2Novo Nordisk Launches Twitter Page with Race Car Driver Charlie Kimball 50608 1Novo Nordisk Launches Twitter Page with Race Car Driver Charlie Kimball 50608 2Novo Nordisk Launches Twitter Page with Race Car Driver Charlie Kimball 50608 3Novo Nordisk Launches Twitter Page with Race Car Driver Charlie Kimball 50608 4Novo Nordisk Launches Twitter Page with Race Car Driver Charlie Kimball 50608 5New Study Shows Many Unplanned Quit Smoking Attempts are Successful 50605 1New Study Shows Many Unplanned Quit Smoking Attempts are Successful 50605 2| Copyright © 2003-2009 Bio-Medicine. All rights reserved. ABOUT | CONTACT US | DISCLAIMER | PRIVACY POLICY | TERMS AND CONDITIONS |  |